Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-HN and SEQ-HN Study of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma
2018-001437-40Phase 2Active
- Sponsor
- Kura Oncology
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib in head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma (SCC) (2 arms), sponsored by Kura Oncology. Primary endpoint: Objective Response Rate. Started Nov 2018; status: active.
02
Drugs
tipifarnib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on 2018-001437-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001437-40.